this month in jnmdepart- ments -...

3
18 F-FDOPA and neuroendocrine tumors: Minn and colleagues provide an overview of the use of this tracer in PET and PET/CT imaging of neuroendocrine tumors, pancre- atic b-cell hyperplasia, and other disorders and discuss future applications in diagnosis and therapy . ............... Page 1915 Improving lung scintigraphy: Parker pre- views 2 articles on lung scintigraphy in this issue of JNM and reviews the current status of the procedure in the diagnosis of acute pulmonary embolism....... Page 1919 Nonrigid registration of chest PET/CT: Grgic and colleagues apply intraindividual analysis to determine whether a nonrigid registration algorithm can improve fusion quality of 18 F-FDG PET and CT thoracic images and describe optimal breathing protocols. ................. Page 1921 Tracers in pulmonary NET tumors: Kayani and colleagues compare the performance of 68 Ga-DOTATATE, a novel selective so- matostatin receptor 2 ligand, and 18 F-FDG in detection of pulmonary neuroendocrine tumors. ..................... Page 1927 Fitted input function to estimate MR glc : Vriens and colleagues report on and validate a mathematic function to describe the arterial plasma time–activity concentration curve for quantification of glucose metabolic rate and therapy response monitoring with dynamic 18 F-FDG PET . .............. Page 1933 18 F-FDG PET in HNSCC follow-up: Krabbe and colleagues assess the role and timing of serial 18 F-FDG PET scans as surveillance for early locoregional recurrence, distant metastases, and second primary tumors after treatment for advanced head and neck squamous cell carcinoma. ...... Page 1940 18 F-FDG and 62 Cu-ATSM in lung cancer: Lohith and colleagues delineate intratumoral uptake and tracer distribution of 62 Cu-ATSM, a hypoxic imaging tracer, and 18 F-FDG in patients with lung cancer of pathohistologi- cally different types............ Page 1948 Cerebral P-gp inhibition by tariquidar: Wagner and colleagues use PET with (R)- 11 C-verapamil, a permeability gluco- protein (P-gp) substrate, to measure P-gp function at the human blood–brain barrier after administration of tariquidar, a potent P-gp inhibitor ............ Page 1954 11 C-MET PET and glioma progression: Ullrich and colleagues investigate the potential of 11 C-MET PET to detect tumor progression in patients with gliomas and assess changes in tracer uptake and molecular immunohistochemical markers during progression. ....... Page 1962 Ischemia in cerebral amyloid angiopathy: Chung and colleagues use 99m Tc-ECD brain perfusion SPECT to characterize cerebral hypoperfusion in patients with cerebral amyloid angiopathy ........... Page 1969 Reference tissue models in BBB disruption: Folkersma and colleagues assess and validate a simplified reference tissue model for ana- lyzing dynamic (R)- 11 C-PK11195 scans in traumatic brain injury, where blood–brain barrier disruptions are likely . .... Page 1975 Endothelial dysfunction in diabetes: Djaberi and colleague explore the diag- nostic challenge presented by diabetic patients with myocardial perfusion defects but no evidence of obstructive epicardial coronary disease.......... Page 1980 V/Q SPECT and low-dose CT vs. MDCT in PE: Gutte and colleagues compare the diagnostic abilities of ventilation–perfusion (V/Q) SPECT, V/Q SPECTwith low-dose CT, and pulmonary multidetector CT angiography with a combined SPECT/MDCT scanner in pulmonary embolism. ......... Page 1987 Cerebral blood flow in diabetes: Ka ´pla ´r and colleagues look for differences in global or regional cerebral blood flow resulting THIS MONTH IN JNM 11A by on October 12, 2019. For personal use only. jnm.snmjournals.org Downloaded from

Upload: others

Post on 30-Aug-2019

1 views

Category:

Documents


0 download

TRANSCRIPT

This Month in JnmDEPART-MENTS

18F-FDOPA and neuroendocrine tumors:Minn and colleagues provide an overview ofthe use of this tracer in PET and PET/CTimaging of neuroendocrine tumors, pancre-atic b-cell hyperplasia, and other disordersand discuss future applications in diagnosisand therapy. . . . . . . . . . . . . . . . Page 1915

Improving lung scintigraphy: Parker pre-views 2 articles on lung scintigraphy in thisissue of JNM and reviews the current statusof the procedure in the diagnosis of acutepulmonary embolism. . . . . . . Page 1919

Nonrigid registration of chest PET/CT:Grgic and colleagues apply intraindividualanalysis to determine whether a nonrigidregistration algorithm can improve fusionquality of 18F-FDG PET and CT thoracicimages and describe optimal breathingprotocols. . . . . . . . . . . . . . . . . . Page 1921

Tracers in pulmonary NET tumors: Kayaniand colleagues compare the performanceof 68Ga-DOTATATE, a novel selective so-matostatin receptor 2 ligand, and 18F-FDGin detection of pulmonary neuroendocrinetumors. . . . . . . . . . . . . . . . . . . . . .Page 1927

Fitted input function to estimate MRglc:Vriens and colleagues report on and validatea mathematic function to describe the arterialplasma time–activity concentration curve forquantification of glucose metabolic rate andtherapy response monitoring with dynamic18F-FDG PET. . . . . . . . . . . . . . . Page 1933

18F-FDG PET in HNSCC follow-up:Krabbe and colleagues assess the role and

timing of serial 18F-FDG PET scans assurveillance for early locoregional recurrence,distant metastases, and second primary tumorsafter treatment for advanced head and necksquamous cell carcinoma. . . . . . .Page 1940

18F-FDG and 62Cu-ATSM in lung cancer:Lohith and colleagues delineate intratumoraluptake and tracer distribution of 62Cu-ATSM,a hypoxic imaging tracer, and 18F-FDG inpatients with lung cancer of pathohistologi-cally different types. . . . . . . . . . . .Page 1948

Cerebral P-gp inhibition by tariquidar:Wagner and colleagues use PET with(R)-11C-verapamil, a permeability gluco-protein (P-gp) substrate, to measure P-gpfunction at the human blood–brain barrierafter administration of tariquidar, a potentP-gp inhibitor. . . . . . . . . . . . Page 1954

11C-MET PET and glioma progression:Ullrich and colleagues investigate thepotential of 11C-MET PET to detect tumor

progression in patients with gliomas andassess changes in tracer uptake andmolecular immunohistochemical markersduring progression. . . . . . . . Page 1962

Ischemia in cerebral amyloid angiopathy:Chung and colleagues use 99mTc-ECD brainperfusion SPECT to characterize cerebralhypoperfusion in patients with cerebralamyloid angiopathy. . . . . . . . . . . Page 1969

Reference tissue models in BBB disruption:Folkersma and colleagues assess and validatea simplified reference tissue model for ana-lyzing dynamic (R)-11C-PK11195 scans intraumatic brain injury, where blood–brainbarrier disruptions are likely. . . . .Page 1975

Endothelial dysfunction in diabetes:Djaberi and colleague explore the diag-nostic challenge presented by diabeticpatients with myocardial perfusion defectsbut no evidence of obstructive epicardialcoronary disease. . . . . . . . . . Page 1980

V/Q SPECT and low-dose CT vs. MDCTin PE: Gutte and colleagues compare thediagnostic abilities of ventilation–perfusion(V/Q) SPECT, V/Q SPECTwith low-dose CT,and pulmonary multidetector CTangiographywith a combined SPECT/MDCT scanner inpulmonary embolism. . . . . . . . . .Page 1987

Cerebral blood flow in diabetes: Kaplarand colleagues look for differences in globalor regional cerebral blood flow resulting

THIS MONTH IN JNM 11A

by on October 12, 2019. For personal use only. jnm.snmjournals.org Downloaded from

from microvascular damage in types 1 and 2diabetes mellitus. . . . . . . . . . . Page 1993

SPECT for pulmonary embolism: Steinand colleagues provide an educational over-view on the current status and accuracy ofSPECT in acute pulmonary embolism anddiscuss its role in the context of increased useof CT angiography. . . . . . . . . . . . Page 1999

Pretargeted RIT of pancreatic cancer:Karacay and colleagues report on a novelpretargeting procedure for therapeutic de-livery of 90Y-labeled PAM4 IgG, a mono-clonal antibody that recognizes a uniqueepitope associated with a mucin in pan-creatic cancer. . . . . . . . . . . . Page 2008

177Lu-AMBA in GRP-R prostate cancer:Maddalena and colleagues evaluate thetumor binding and imaging potential ofthis radiolabeled bombesin derivative inlow gastrin-releasing peptide receptormodels of prostate cancer and determinehow reduced expression affects radiother-apeutic efficacy. . . . . . . . . . . Page 2017

Systemic radionuclide therapy and glio-mas: Samnick and colleagues test thetherapeutic potential of 131I-IPA, a tumor-specific amino acid derivative, combinedwith external-beam photon radiotherapy inglioma-bearing rats. . . . . . . . Page 2025

RIT with 125I-mAbs: Santoro and col-leagues assess the in vivo biologic efficiency

of internalizing and noninternalizing 125I-labeled monoclonal antibodies for the treat-ment of small solid tumors. . . . . Page 2033

18F-labeled phosphoramidate: Lapi andcolleagues report on studies exploring phos-phoramidates as novel small-molecule pros-tate-specific membrane antigen inhibitorsto develop more effective prostate cancerimaging agents with improved specificityand clearance properties. . . . . . . Page 2042

Mutant TK/GFP fusion reporter: Hsiehand colleagues construct a mutant thymidinekinase/green fluorescent protein reportergene with low cytotoxicity and high temporalresolution for real-time optical and PETmonitoring of transcription induction andother biochemical changes. . . . . Page 2049

Imaging VEGF receptors in abscesses:Levashova and colleagues determinewhether labeled forms of single-chainvascular endothelial growth factor (VEGF)can be used to image VEGF receptors in ananimal model of sterile soft-tissue inflam-mation. . . . . . . . . . . . . . . . . Page 2058

PET radioligand for H3 receptors: Plissonand colleagues synthesize and evaluate thepotential utility of 11C-GSK189254, a hista-mine H3 receptor antagonist, for PETimaging of these receptors. . . . . Page 2064

Therapy and 111In-vinorelbine liposomes:Chow and colleagues investigate the thera-peutic effectiveness of specific amounts ofthese PEGylated liposomes by varyingradiation dosage and concentrations ofchemotherapeutic agents in animal tumorgrowth suppression studies. . . . . Page 2073

Radiolabeled divalent gastrin peptide:Sosabowski and colleagues expand onprevious studies of 111In-labeled divalentgastric peptides with potential for radio-nuclide therapy in tumors overexpressinggastrin/cholecystokinin subtype 2 recep-tors. . . . . . . . . . . . . . . . . . . Page 2082

O N T H E C O V E R

Both ventilation–perfusion SPECT and multidetector CT angiographyhave high accuracy in the diagnosis of pulmonary embolism, butonly limited data comparing the two are available. A prospectivestudy using a hybrid scanner has concluded that ventilation–perfusionSPECT in combination with unenhanced low-dose CT has excellentdiagnostic performance and should probably be considered first-lineimaging in the work-up of most cases of pulmonary embolism.

See page 1990.

12A THE JOURNAL OF NUCLEAR MEDICINE • Vol. 50 • No. 12 • December 2009

by on October 12, 2019. For personal use only. jnm.snmjournals.org Downloaded from

2009;50:11A-12A.J Nucl Med.     This Month in JNM

http://jnm.snmjournals.org/content/50/12/11AThis article and updated information are available at:

  http://jnm.snmjournals.org/site/subscriptions/online.xhtml

Information about subscriptions to JNM can be found at:  

http://jnm.snmjournals.org/site/misc/permission.xhtmlInformation about reproducing figures, tables, or other portions of this article can be found online at:

(Print ISSN: 0161-5505, Online ISSN: 2159-662X)1850 Samuel Morse Drive, Reston, VA 20190.SNMMI | Society of Nuclear Medicine and Molecular Imaging

is published monthly.The Journal of Nuclear Medicine

© Copyright 2009 SNMMI; all rights reserved.

by on October 12, 2019. For personal use only. jnm.snmjournals.org Downloaded from